Biopharmaceutical
Pharmaceutical
Cancer Prevention

Pieris Pharmaceuticals

$5.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.10 (2.04%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell PIRS and other stocks, options, ETFs, and crypto commission-free!

About PIRS

Pieris Pharmaceuticals, Inc. Common Stock, also called Pieris Pharmaceuticals, is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Read More Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Employees
107
Headquarters
Boston, Massachusetts
Founded
2001
Market Cap
246.97M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
422.02K
High Today
$5.06
Low Today
$4.91
Open Price
$4.98
Volume
614.72K
52 Week High
$6.04
52 Week Low
$2.39

Collections

Biopharmaceutical
Pharmaceutical
Cancer Prevention
Medical
Biotechnology
Technology
Health
2015 IPO

PIRS Earnings

-$0.24
-$0.10
$0.04
$0.18
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 7, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.